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Results: T/M rations for PSVue®794 were
200% times higher than for PSVue®643 (P =
<0.05). Both probes showed 25%-30%
increased T/M ratios post DOX treatment, (P =
<0.05) indicative of enhanced apoptosis. With
PSVue®643 tumor intensity declined over time,
but increased for intestine. With PSVue®794
tumor intensity and T/M ratios increased as a
function of time, with a decreased M/O ratios for
all organs.
OPTICAL IMAGING FOR DETERMINATION OF APOPTOSIS MEDICATED THERAPEUTIC EFFICACY
K Zhang, PhD1, B. Paudyal, PhD1, N. Mehta1, B Gray, PhD4, C Pak, PhD4, E Wickstrom, PhD2,3, M. Thakur, PhD1,3
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Conclusion: OI of apoptotic BC cells mediated by DOX treatment permits to determine the effectiveness of DOX within 24 hrs. These results are consistent with those in another
investigation in which F-18-FDG was used to monitor diminished metabolic activity following DOX treatment. PSVue®794 which eliminates radiation burden to normal organs is a
preferable NIR fluorophore for determination of therapeutic effectiveness of BC by OI. Support: NIH 1S10 RR026678-01 (MLT).
Structure of PSVue794®Structure of PSVue643®Hallmarks of the Apoptotic and Necrotic Cell Death Process
A Non-Specific fluorophore PSVue643 fails to
have increased tumor uptake post-DOX treatment
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Note increased tumor uptake of PSVue794
at 24 hr. post-DOX treatment.
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Data suggest that PSVue794 is a preferable NIR fluorophore
for determination of Doxorubicin effectiveness.
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Increased intestine uptake of PSVue643 indicates hepatobiliary excretion®
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Histologic Presentation of
Untreated BT474 Tumor (x 40)
Histologic Presentation of DOX
Treated BT474 Tumor. Apoptotic
Cells are Visible (arrow)
Objectives: Targeting apoptosis to assess therapeutic
response is uncommon. The purpose was to evaluate
the use of two near infrared (NIR) fluorophores to
monitor the effectiveness of breast cancer (BC) therapy.
Both fluorophores have high affinity for
phosphatidylserine (PS) released on the outer leaflet of
apoptotic cells medicated by therapeutic intervention.
The long term goal is to determine if optical imaging (OI)
can play a vital role in determination of therapeutic
efficacy noninvasively.
Methods: Two NIR fluorophores linked bis-zinc (II)
dipicolylamine coordination complexes, PSVue®643 and
PSVue®794, served as the probes. Athymic nude mice
bearing human BC tumors BT474, received 16.5 µg of one of
the NIR probes i.v. before and after 40 µg of doxorubicin
(DOX) given once I.P. OI was performed up to 24 hrs post
injection (PSVue®643; Abs. 643 nm; Em. 658 nm;
PSVue®794; Abs. 794 nm; Em. 810 nm). Tumor/muscle
(T/M) and organ/muscle (O/M) ratios were calculated and
plotted.
